+91-33-4600-9199  (India), +1-414-240-5010 (U.S.)
Systemic Scleroderma Treatment Market is expected to witness 8.06% CAGR between 2021-2031- Market Insights, Size, Share, Growth, Trends, Analysis, and Forecast
Published : May 2021

According to a new market research report published by sheer analytics and insights, "The Global Systemic Scleroderma Treatment Market was valued at $1.80 Billion in 2020. Growing at a high CAGR of more than 8.06% between 2021 and 2031, it is estimated to reach $4.3 Billion by 2031", as per the latest market research report titled Global Systemic Scleroderma Treatment Market - Industry analysis, size, share, growth, trends and forecast, 2021 – 2031.

The supplemental approvals for the current treatment options and the emergence of first-in-class therapies that are currently under development will help accelerate the growth of this market during the forecasted period. The off-label use of the drugs approved for their symptomatic indications, like rheumatoid arthritis, will also help the market grow. So, the lack of curative therapies and the high prevalence of off-label drug use are the main factors that will help to boost the growth of this market.

Some important approvals and updates in this field:

  • In November 2021, U.S. FDA approved a supplemental new drug application from ANI Pharmaceuticals. A new drug known as Cortrophin Gel effectively treats multiple sclerosis, rheumatoid arthritis, and certain other autoimmune diseases.
  • In November 2021, Amylyx Pharmaceuticals is seeking approval in the U.S. for its investigational therapy AMX0035, slowing functional decline in people with amyotrophic lateral sclerosis (ALS).
  • In October 2021, D&D Pharmatech raised $51M in Series C Financing for Advance Potential Disease-Modifying Treatments for Fibrotic, Neurodegenerative, and Metabolic Diseases
  • In September 2021, Sanofi merged with Kadmon, which developed belumosudil (KD025), an oral investigational treatment for patients with the diffuse cutaneous form of systemic sclerosis (dcSSc). Belumosudil, sold under the brand name Rezurock, was recently approved by the U.S. FDA for patients above 12 years of age suffering from chronic graft-versus-host disease (cGVHD).
  • According to a STEM CELLS Translational Medicine journal, April 2021, Fat grafts enhanced with ADSCs show promise in treating facial scleroderma
  • In March 2021, The U.S. Food and Drug Administration (FDA) approved Actemra (tocilizumab) for treating adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

The Global Systemic Scleroderma Treatment Market is geographically divided into North America, Europe, Asia- Pacific, Latin America, Middle East, and Africa. North America will lead the market for treating systemic scleroderma in 2021, with a share of more than 43% and is expected to remain dominant through the forecast period.

Click full report at https://www.sheeranalyticsandinsights.com/market-report-research/systemic-scleroderma-treatment-market-21

List of Companies Covered:

  • Boehringer Ingelheim International GmbH
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Among Others

The Global Systemic Scleroderma Treatment Market Has Been Segmented Into:

Global Systemic Scleroderma Treatment MarketBy Drug Class

  • Immunosuppressors
  • Phosphodiesterase 5 inhibitors – PHA
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Calcium Channel Blockers
  • Others

Global Systemic Scleroderma Treatment Market, By Country

  • North America
    • USA
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America, Middle East & Africa
    • Brazil
    • South Africa
    • UAE
    • Rest of LAMEA

Request a Sample Copy of Report: https://www.sheeranalyticsandinsights.com/request-sample/systemic-scleroderma-treatment-market-21

About Us     

Sheer Analytics and Insights Private Limited is market research, consulting, and IT services company. We as a company believe in providing point to point data and its analysis with the combination of our human and automation integration. Sheer Analytics and Insights cover majorly eight industry verticals, including chemicals, life science, communications, and electronics, materials, consumer goods, defense, and BFSI sector.

Sheer Analytics believes in quality work and ensures that the product delivered to the client is meaningful for them. We publish reports based on our advanced analytics reports, which are generated with the help of our in-house databases, external databases, and artificial intelligence integration processes. We stand out from other market research companies in terms of integrating facts with meaningful insights for forecasting.

Apart from publishing syndicated reports (mostly client reports), we are dealing with projects primarily based on “Go to Market Strategy, Data Mining and Extraction,” meaning full data analysis based on big data and many other database services and content related services.

Our products include quick turnaround datasets, TAM/PAM Analysis to full-fledged deep dive research on top trending markets.

 

Contact:

Abhigyan Sengupta

Sheer Analytics and Insights

Email: query@sheeranalyticsandinsights.com

+1-414-240-5010

Website: https://www.sheeranalyticsandinsights.com/

 

Registered Office
RDB Boulevard, 8th Floor, Plot K 1, Sector 5, Block EP and GP, Kolkata 700091, India.
Contact Us
+91-33-4600-9199
+1-414-240-5010
sales@sheeranalyticsandinsights.com
Stay Informed
Submit Your Query
Hot Links